January 7th 2026
CARMAT (FR0010907956, ALCAR, eligible for the PEA-PME scheme), designer and developer of the world’s most advanced total artificial heart (the “Company” or “CARMAT” or “CARMAT SA”), aiming to offer a therapeutic alternative to patients suffering from advanced biventricular heart failure, today announces its judicial liquidation and its delisting.
As a reminder, CARMAT was placed under judicial reorganization by the Versailles Economic Activities Court (the “Court”) on July 1, 2025. Subsequently, by a ruling dated December 1, 2025, the Court approved the disposal plan of the Company in favor of “CARMAT SAS”, a simplified joint-stock company incorporated for the purposes of the acquisition. The Company’s activities are therefore now continuing and are operated by CARMAT SAS.
In this context, by a ruling dated January 6, 2026, the Court pronounced the judicial liquidation of CARMAT SA.
The liquidator will therefore shortly apply to Euronext Growth for the delisting of the Company’s shares. In the meantime, trading in CARMAT shares (ISIN: FR0010907956, Ticker: ALCAR) remains suspended and will not resume.
The Company again reminds that, given the level of its liabilities and the terms of the acquisition, it is highly likely that a large portion of its creditors will suffer a very significant loss, potentially affecting the entirety of their claims, and it is now certain that CARMAT shareholders will incur the total loss of their investment.